Tigecycline and Liver Enzyme Elevations
Tigecycline, a glycylcycline antibiotic, can cause liver enzyme elevations signaling potential hepatotoxicity. These changes are typically asymptomatic and reversible upon discontinuation, but monitoring is recommended, especially in patients with liver impairment.[1]
Which Enzymes Are Affected
- Alanine aminotransferase (ALT): Most common elevation, reported in up to 25% of patients in clinical trials. Levels often exceed 3x upper limit of normal (ULN).[1][2]
- Aspartate aminotransferase (AST): Frequently rises alongside ALT, in about 20-25% of cases.[1]
- Alkaline phosphatase (ALP): Less common, seen in 10-15% of patients.[2]
- Gamma-glutamyl transferase (GGT): Occasionally elevated, particularly in post-marketing reports.[3]
Bilirubin elevations occur rarely (<2%), usually without jaundice.[1]
Severity and Monitoring Guidelines
Mild to moderate increases (up to 5x ULN) predominate; severe cases (>10x ULN) are infrequent (<1%).[2]
FDA labeling advises baseline liver tests and monitoring every 3 days during treatment, with prompt discontinuation if transaminases exceed 5x ULN or symptoms appear.[1] No specific dose adjustment for mild-moderate liver disease, but caution in severe cases.
How Tigecycline Causes This
Mechanism involves direct hepatocyte stress from mitochondrial inhibition, leading to transaminase leakage. Risk factors include prolonged use (>14 days), IV formulation, and comorbidities like fatty liver.[3][4]
Clinical Trial and Real-World Data
In phase 3 trials (n>5,000), 13-26% had ALT/AST rises vs. 9-15% comparators (e.g., vancomycin). Post-approval surveillance shows similar patterns, with low progression to acute liver injury (<<0.1%).[2][4]
Compared to Other Tetracyclines
Tigecycline shows higher hepatotoxicity rates than doxycycline (ALT rise ~5%) or minocycline (~10%), linked to its biliary excretion and higher doses.[3]
When to Worry: Red Flags
Watch for ALT/AST >5x ULN, rising bilirubin, or symptoms (fatigue, nausea). Rare cases progress to drug-induced liver injury (DILI), but tigecycline Hy's law cases (ALT>3x + bilirubin>2x) are minimal.[4]
Sources:
[1] [Tygacil FDA Label (2010)]
[2] [Meagher et al., Clin Infect Dis (2009)]
[3] [StatPearls: Tigecycline (2023)]
[4] [LiverTox: Tigecycline (NIH, updated 2020)]